NO20012265L - Dispergerbare preparater inneholdende L-DOPA-ethylester - Google Patents

Dispergerbare preparater inneholdende L-DOPA-ethylester

Info

Publication number
NO20012265L
NO20012265L NO20012265A NO20012265A NO20012265L NO 20012265 L NO20012265 L NO 20012265L NO 20012265 A NO20012265 A NO 20012265A NO 20012265 A NO20012265 A NO 20012265A NO 20012265 L NO20012265 L NO 20012265L
Authority
NO
Norway
Prior art keywords
ethyl ester
preparations containing
dopa ethyl
dispersible preparations
dispersible
Prior art date
Application number
NO20012265A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012265D0 (no
Inventor
Galit Levin
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20012265D0 publication Critical patent/NO20012265D0/no
Publication of NO20012265L publication Critical patent/NO20012265L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20012265A 1998-11-10 2001-05-08 Dispergerbare preparater inneholdende L-DOPA-ethylester NO20012265L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10789398P 1998-11-10 1998-11-10
PCT/US1999/026546 WO2000027385A1 (en) 1998-11-10 1999-11-10 Dispersible compositions containing l-dopa ethyl ester

Publications (2)

Publication Number Publication Date
NO20012265D0 NO20012265D0 (no) 2001-05-08
NO20012265L true NO20012265L (no) 2001-07-03

Family

ID=22319025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012265A NO20012265L (no) 1998-11-10 2001-05-08 Dispergerbare preparater inneholdende L-DOPA-ethylester

Country Status (13)

Country Link
US (2) US6376545B1 (hu)
EP (1) EP1135118A1 (hu)
JP (1) JP2002529407A (hu)
CN (1) CN1329487A (hu)
AU (1) AU764742B2 (hu)
CA (1) CA2350304A1 (hu)
HK (1) HK1041441A1 (hu)
HU (1) HUP0104586A3 (hu)
IL (1) IL143071A0 (hu)
NO (1) NO20012265L (hu)
NZ (1) NZ512027A (hu)
WO (1) WO2000027385A1 (hu)
ZA (1) ZA200103527B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143071A0 (en) 1998-11-10 2002-04-21 Teva Pharma Dispersible compositions containing l-dopa ethyl ester
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
AU2002340470A1 (en) 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
EP1670450B8 (en) * 2003-08-29 2011-03-23 Centocor Ortho Biotech Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
US20080063720A1 (en) * 2004-04-29 2008-03-13 Gounko Iouri K Delivery System
WO2006035414A2 (en) * 2004-09-30 2006-04-06 Ranbaxy Laboratories Limited Carbidopa and levodopa dispersible tablets
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008003028A2 (en) * 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
NZ579368A (en) * 2007-03-09 2012-03-30 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
WO2008137923A2 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2010135396A2 (en) 2009-05-19 2010-11-25 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US20130017274A1 (en) * 2011-03-16 2013-01-17 Buck Institute For Research On Aging Low dose lithium in the treatment or prophylaxis of parkinson's disease
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
DE2246013A1 (de) 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US3939253A (en) 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
ATE76747T1 (de) 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
MY110880A (en) 1991-01-30 1999-06-30 The Wellcome Foundation Ltd Water-dispersible tablets
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
IL143071A0 (en) 1998-11-10 2002-04-21 Teva Pharma Dispersible compositions containing l-dopa ethyl ester

Also Published As

Publication number Publication date
IL143071A0 (en) 2002-04-21
US20020151589A1 (en) 2002-10-17
WO2000027385A1 (en) 2000-05-18
ZA200103527B (en) 2002-05-09
NZ512027A (en) 2004-04-30
AU1716800A (en) 2000-05-29
US6376545B1 (en) 2002-04-23
HUP0104586A3 (en) 2002-12-28
JP2002529407A (ja) 2002-09-10
AU764742B2 (en) 2003-08-28
HK1041441A1 (zh) 2002-07-12
EP1135118A1 (en) 2001-09-26
CN1329487A (zh) 2002-01-02
NO20012265D0 (no) 2001-05-08
HUP0104586A2 (en) 2002-06-29
CA2350304A1 (en) 2000-05-18
US6703424B2 (en) 2004-03-09

Similar Documents

Publication Publication Date Title
NO20012265L (no) Dispergerbare preparater inneholdende L-DOPA-ethylester
IS2325B (is) Örgerðar samsetningar epleróns
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO992339L (no) Farmasöytiske formuleringer
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
NO20004240L (no) Formuleringer
IS6040A (is) Valdekoxib efnablöndur
MA24473A1 (fr) Formulations
ATE224703T1 (de) Brauseformulierungen
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
PT1130966E (pt) Formulacoes antiparasitarias
NO20010046D0 (no) Dolastatin-15-derivater
DE59902101D1 (de) Pigmentpräparationen
DE69823830D1 (de) Dermatologische zubereitungen
DE60029602D1 (de) Lipasehemmer enthaltende dispersionsformulierungen
NO993096D0 (no) Orale cyklosporinformuleringer
NO20000231D0 (no) Dolastatin-15-derivater
DE69805807D1 (de) Mikrobiozide n-sulfonylglycin-alkynyloxyphenethylamid-derivate
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
ATE298576T1 (de) Arzneizubereitungen
PT895782E (pt) Preparados farmaceuticos de cilansetron estabilizados contra racemizacao
ATE246494T1 (de) Brausezubereitungen
DE69828796D1 (de) Hochreine verzweigte alkylsilsesquioxanflüssigkeiten